Condition: Age-related Macular Degeneration (AMD) · Sponsor: Assistance Publique - Hôpitaux de Paris
The primary objectives of the study are to assess the safety, tolerability and evidence of activity of 12 months oral treatment with TEFIDERA® in subjects with Geographic Atrophy associated with Age-Related Macular Degeneration (AMD).
This description comes directly from the study's public registry record.
Eric SOUIED, PU-PH · +33 1 45 17 59 08 · eric.souied@chicreteil.fr
Serge Camelo, PHD · sergecamelo2@hotmail.com
Always discuss trial participation with your own doctor first.
| Centre intercommunal de Créteil | Créteil, Val De Marne, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04292080